Published in Drug Metab Dispos on December 01, 1996
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol (2007) 1.81
Cellular and molecular actions of Methylene Blue in the nervous system. Med Res Rev (2011) 1.22
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer (2000) 1.12
Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem Pharmacol (2010) 0.95
Safe thyroidectomy with intraoperative methylene blue spraying. Thyroid Res (2012) 0.81
Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria. Malar J (2014) 0.77
Glycoluril-Derived Molecular Clips are Potent and Selective Receptors for Cationic Dyes in Water. Chemistry (2016) 0.76
[Not Available]. Can J Hosp Pharm (2013) 0.75
In Vitro Protective Effect and Antioxidant Mechanism of Resveratrol Induced by Dapsone Hydroxylamine in Human Cells. PLoS One (2015) 0.75
Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br J Cancer (1998) 0.75
Methylene blue inhibits function of the 5-HT transporter. Br J Pharmacol (2012) 0.75
Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis (2017) 0.75
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol (1984) 2.66
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther (1985) 2.50
Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol (2000) 2.24
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet (1990) 2.05
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer (2006) 1.41
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther (1976) 1.35
Preclinical development of a vaccine 'against smoking'. Onkologie (2002) 1.33
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer (1987) 1.26
Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet (1984) 1.26
Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther (1984) 1.25
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol (1997) 1.22
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
Inherited defects of hepatic drug metabolism. Semin Liver Dis (1983) 1.17
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet (1994) 1.15
Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol (2008) 1.10
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer (2008) 1.05
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie (2002) 1.05
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets (2010) 1.03
Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther (1987) 1.03
Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther (1981) 1.00
Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica (1986) 1.00
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol (1996) 0.99
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Schweiz Med Wochenschr (1982) 0.99
Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol (2000) 0.98
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.97
Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med (2007) 0.97
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer (2010) 0.97
Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther (1982) 0.94
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol (1989) 0.94
Ifosfamide by continuous infusion to prevent encephalopathy. Lancet (1990) 0.94
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther (1985) 0.93
A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr (1986) 0.91
Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma. Eur J Nucl Med (1987) 0.91
Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol (1986) 0.90
Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol (1997) 0.90
Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol (1986) 0.90
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol (2006) 0.90
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol (1994) 0.89
Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res (1991) 0.89
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol (2006) 0.88
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines. Cancer Res (1989) 0.88
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos (1998) 0.87
Relapse and subarachnoid dissemination of a pineal germinoma 14 years after radiation therapy. J Clin Neurosci (1999) 0.85
The cognitive-spiritual dimension--an important addition to the assessment of quality of life: validation of a questionnaire (SELT-M) in patients with advanced cancer. Ann Oncol (1998) 0.85
Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol (1995) 0.85
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol (2002) 0.85
Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. Eur J Haematol (1999) 0.84
Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. Schweiz Med Wochenschr (2000) 0.84
Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer (2012) 0.83
Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol (1997) 0.83
Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol (1999) 0.83
Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos (1998) 0.83
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1999) 0.83
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol (2014) 0.83
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome. Eur J Clin Invest (1978) 0.82
Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection. Clin Chem Lab Med (2001) 0.82
Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography. J Chromatogr (1982) 0.82
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer (1994) 0.82
The differential localization of various drug metabolizing systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride and bromobenzene. J Pharmacol Exp Ther (1981) 0.82
Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol (1998) 0.81
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol (2006) 0.81
A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab Dispos (1980) 0.81
The enigma of ifosfamide encephalopathy. Ann Oncol (1992) 0.81
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol (1986) 0.81
Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. J Pharmacol Exp Ther (1984) 0.81
Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. J Gastrointest Surg (2014) 0.81
Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma. Eur J Cancer Clin Oncol (1989) 0.80
Primary cervical malignant teratoma with a rib metastasis in an adult: five-year survival after surgery and chemotherapy. A case report with a review of the literature. Ann Oncol (1998) 0.80
Patterns of drug resistance parameters in adult leukemia. Leuk Lymphoma (1995) 0.80
Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol (1999) 0.80
Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol (1991) 0.80
The proteasome, a new target for cancer therapy. Onkologie (2002) 0.79
Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Ann Oncol (1992) 0.79
The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol (1990) 0.79
Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer (2009) 0.79
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. Ann Oncol (1990) 0.79
Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat. Drug Metab Dispos (1981) 0.79
[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. Schweiz Med Wochenschr (1989) 0.78
Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol (1993) 0.78
Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol (1997) 0.78
Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and of methods of assessing compliance. Dev Med Child Neurol (1981) 0.78